Section Arrow
VCEL.NASDAQ
- Vericel Corp
Quotes are at least 15-min delayed:2025/07/21 06:34 EDT
Pre Market
Last
 36.68
+1.34 (+3.79%)
Bid
18
Ask
39.88
High 36.68 
Low 36.58 
Volume 13 
Regular Hours
Last
 35.34
-0.92 (-2.54%)
Day High 
37.09 
Prev. Close
36.26 
1-M High
43.57 
Volume 
545.08K 
Bid
18
Ask
39.88
Day Low
35.18 
Open
36.89 
1-M Low
35.955 
Market Cap 
1.83B 
Currency USD 
P/E 742.4 
%Yield -- 
10-SMA 39.43 
20-SMA 40.71 
50-SMA 41.59 
52-W High 63 
52-W Low 35.18 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
0.05/0.99
Enterprise Value
1.92B
Balance Sheet
Book Value Per Share
5.87
Cash Flow
Cash Flow Yield
0.03
Income Statement
Total Revenue
237.22M
Operating Revenue Per Share
3.68
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TELOTelomir Pharmaceuticals2.28+1.07+88.43%-- 
Pre Market 2.01 -0.27 -11.84%
SRPTSarepta Therapeutics14.075-7.895-35.94%15.76PE
Pre Market 13.43 -0.645 -4.58%
NCNANuCana plc0.0477+0.0009+1.92%-- 
Pre Market 0.0474 -0.0003 -0.63%
RXRXRecursion Pharmaceuticals5.84+0.32+5.80%-- 
Pre Market 6.195 +0.355 +6.08%
MEIPMEI Pharma5.92+1.42+31.56%1.09PE
Pre Market 6.03 +0.11 +1.86%
Quotes are at least 15-min delayed:2025/07/21 06:34 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.